2023
Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study
Clark E, Perin J, Herrmann N, Brawman‐Mintzer O, Lanctôt K, Lerner A, Mintzer J, Padala P, Rosenberg P, Sami S, Shade D, van Dyck C, Porsteinsson A, Group F. Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2023, 9: e12403. PMID: 37538343, PMCID: PMC10394740, DOI: 10.1002/trc2.12403.Peer-Reviewed Original ResearchNeuropsychiatric symptomsEffects of methylphenidateAlzheimer's diseaseSecondary analysisNeuropsychiatric Inventory scoresElation/euphoriaSymptoms of apathyIndividual neuropsychiatric symptomsPresentation of symptomsImpact of methylphenidateIndividual domain scoresAppetite/Catecholaminergic dysfunctionMonth 6Neuropsychiatric InventoryCaregiver scoresNPI domainsNew symptomsTreatment periodDomain scoresMeaningful improvementsMethylphenidateSymptomsPlaceboDisease
2020
Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate
van Dyck CH, Arnsten AFT, Padala PR, Brawman-Mintzer O, Lerner AJ, Porsteinsson AP, Scherer RW, Levey AI, Herrmann N, Jamil N, Mintzer JE, Lanctôt KL, Rosenberg PB. Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate. American Journal Of Geriatric Psychiatry 2020, 29: 51-62. PMID: 32461027, PMCID: PMC7641967, DOI: 10.1016/j.jagp.2020.04.026.Peer-Reviewed Original ResearchConceptsTreatment of apathyAlzheimer's diseaseCortical-basal ganglia circuitsPrefrontal cortexMotivated behaviorPublic health burdenSymptoms of apathyCatecholaminergic treatmentNeurobiologic rationaleNeuropsychiatric symptomsDopamine actionGanglia circuitsHealth burdenThalamocortical circuitsCognitive symptomsMethylphenidate actionsCatecholamine actionNeuronal circuitsSymptomsDiseaseApathetic behaviorTreatmentInitial trialMethylphenidateAD results